Summary: Steady-state plasma valproate (VPA) levels were analyzed in 37 children after 6 weeks of VPA therapy. Twenty-six patients were receiving other antiepileptic drugs in addition to VPA (experimental group). Eleven patients who received VPA alone served as controls. The mean VPA dose was not statistically different for the two groups (experimental group, 35.4 mglkgl day, 11.6 SD; control group, 31.1 mg/kg/day, SD 6.6) The mean plasma VPA level was significantly lower for the experimental group (63.0 pglml, SD 21.8) than for the control (99.3 pglmI), SD 23.3) (p < 0.01). VPA 1evel:dose ratio (LDR) was also reduced in the experimental group (1.92, SD 0.75) as compared to controls (3.26, SD 0.65) (p < 0.01). Within' the experimental group the VPA levels and VPA LDR were significantly reduced in patients receiving either phenytoin or phenobarbital. The data suggest that other antiepileptic drugs significantly alter the steady-state level to dose relationship for VPA.
Since valproic acid (VPA) is useful as an adjunctive drug for controlling several seizure types (Simon and Penry, 1975; Pinder et al., 1977) , it is frequently administered to patients receiving other antiepileptic drugs (AEDs). Interactions between VPA and other AEDs have been reported. VPA may affect the pharmacokinetics of phenytoin (Patsalos and Lascelles, 1977; Mattson et al., 1978; Bruni et al., 1979; Cramer and Mattson, 1979) , phenobarbital (Schobben et al., 1975; Gram et al, 1977; Wilder et al., 1978) , and ethosuximide (Mattson and Cramer, 1980) . Other AEDs also affect the kinetics of VPA. After administering a single oral or intravenous dose of VPA to patients already receiving both phenytoin and phenobarbital, the volume of distribution is larger and the elimination rate higher than the same parameters measured in normal controls (Richens et al., 1976; Perucca et al., 1978) . Vajda et al. (1978) reported a flattening of the steady-state plasma level to dose curve with higher doses of VPA, suggesting drug interactions affecting VPAlevels. Bowdle et al. (1979) reported a de-
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cline in the minimum steady-state serum concentrations of VPA following 2 weeks of treatment with carbamazepine. In the present study, we found steady-state plasma VPA 1evel:dose ratios (LDR) to be lower in children receiving other AEDs than in children receiving VPA alone.
MATERIALS AND METHODS
VPA plasma levels were analyzed in 37 children with absence seizures (ages 3% to 1811/12 years) who received VPA during a double-blind crossover study comparing VPA and ethosuximide. Twenty-six patients (experimental group) were receiving other AEDs at the time of entry into the study. In this group, VPA was given in addition to the drug or drugs taken at the time of entry. The control group consisted of 11 patients who received only VPA. The ages of the patients in the two groups were not significantly different.
VPA was begun in doses of 10-15 mg/ kg/day. Doses were administered orally at 0700, 1500, and 2300 hr daily. During the first 2 weeks of VPA therapy, the dose was increased in 5-15 mg/kg/day increments until the maximum tolerated dose or 60 mg/kg/day was reached. The doses of the concurrent AEDs were kept constant unless side effects attributable to alterations in the plasma levels of these drugs occurred. In these cases, the dose of the responsible drug was adjusted to return the plasma level of that drug to the pre-entry level. No drug changes were made after 4 weeks of VPA therapy. Neither the physician nor the patients knew that the active drug was VPA, and the physician was unaware of the VPA level during the course of the study.
For purposes of the present study, drug levels obtained after 6 weeks of VPA therapy were analyzed. Blood samples were obtained at 0655 hr, prior to the 0700 hr dose. Drug levels were assayed by gasliquid chromatography (Kupferberg, 1978) .
RESULTS
The mean plasma VPA level and LDRs were significantly lower in the experimental group than in the control group. The mean VPA dosages and body weights were not significantly different (Table 1 ). Figure 1 shows the relationship between VPA plasma level and VPA dose for both groups. This relationship was more nearly linear for the control group than for the experimental group, and the slope of the linear regression line was steeper (2.29) for the control group than for the experimental group (0.40).
To assess the role of individual drugs affecting VPA plasma levels, the patients in the experimental group were further divided according to treatment. For the six patients who received phenobarbital and VPA, the LDR of VPA (1.80 r 0.68, mean & SD) was significantly less than those of patients in the control group (p < 0.01).
There was no correlation between the phenobarbital level and the LDR for VPA. For the three patients who received phenytoin in addition to VPA, the LDR for VPA (1.35 2 0.34) was lower than that of the control group (p < 0.01). The VPA LDR was also significantly lower than those of Only one patient received mephobarbital alone in addition to VPA. In this patient, the LDR for VPA was over two standard deviations lkss than that of the control group. For the patient who received primidone in addition to VPA, the LDR for VPA was 3.29, very close to the mean LDR for the control group. One patient received only carbamazepine in addition to VPA. The LDR for this patient was 2.73, less than one standard deviation below that of the mean LDR for the controls. The remaining 12 patients in the experimental group received two or more drugs in addition to VPA.
ALTERATION OF PLASMA V P A LEVELS

DISCUSSION
The steady-state LDR of VPA was significantly lower in patients receiving phenytoin, phenobarbital, or both phenytoin and phenobarbital. The effects of phenytoin and phenobarbital were not additive. The effects of the other AED steady-state VPA plasma levels could not be determined because of the small number of patients in these groups.
There was good correlation between the daily dose and plasma level when VPA was administered as a sole therapy (control group). However, there was poor correlation betweeen the daily dose and plasma level for subjects receiving other AEDs. The slope of the level to dose curve for the experimental group is much steeper than that of the control group (Fig. 1) . This suggests that when VPA is used as sole therapy, a change in the daily maintenance dose will result in much larger changes in the steady-state plasma levels than would be expected in patients also receiving phenytoin or phenobarbital.
Drug interactions of the magnitude observed in this study confound predictions of steady-state plasma levels. Therefore, close monitoring of VPA plasma levels is required until steady state is achieved. VPA LDRs may also change following dosage changes or discontinuation of other AEDs and the time to reach new steady-state VPA levels is not known.
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The maximum tolerated doses were similar for subjects receiving other AEDs and those receiving VPA alone, even though the plasma levels were significantly lower in those receiving other drugs. This suggests that there was synergistic toxicity or that the dose-limiting side effects (drowsiness or nausea) were due to high free-fractions of VPA or phenytoin, or higher concentration of active metabolites of VPA as a result of hepatic enzyme-induction. The presence of phenytoin, at least in high concentrations, increases the plasma free-fraction of VPA (Cramer and Mattson, 1979; Monks et al., 1978) . The magnitude of this effect at steady state is not known, but probably varies with the concentration of both drugs. Since VPA is highly protein bound (Klotz and Antonin, 1977; Gugler and Mueller, 1978; Cramer and Mattson, 1979) , small increases in the free fraction of VPA could result in significant changes in both toxic and therapeutic effects. Therefore, the lower total VPA levels in patients who were receiving phenytoin may not accurately reflect the biological activity of VPA. Measurement of the free fraction as well as total VPA levels may more accurately reflect the biological activity, particularly when VPA is used in combination with phenytoin.
Since the elimination of VPA from plasma is of the flow-independent restrictive type, only the unbound drug can be cleared (Klotz and Antonin, 1977) . Therefore, an increase in the free fraction of VPA could have contributed to the lower steady-state VPA concentrations observed in patients receiving phenytoin. Any drug which competes with VPA for plasma protein binding sites would be expected to have a similar effect. Phenobarbital is approximately 40% bound to plasma protein, (Waddell and Butler, 1957) , and there is no evidence that phenobarbital competes with VPA for plasma protein binding sites. Neither phenytoin or phenobarbital affects gastrointestinal absorption of VPA (Perucca et al., 1978) . Therefore, it is likely that phenobarbital lowers steady-state VPA levels by induction of hepatic enzymes, as suggested by Gugler and Unruh (1980 
ZUSAMMENFASSUNG
In steady-state befindliche Plasma Valproatspiegel (VPA) wurden bei 37 Kindern nach 6 wochiger VPATherapie analysiert. 26 Patienten erhielten zushtzlich zum VPA andere Antiepileptika (experimentelle Gruppe). 11 Patienten, die VPA alleine bekamen, dienten als KontroIlen. Die mittlere VPA-Dosis war in beiden Gruppen nicht signifikant Vunterschiedlich (experimentelle Gruppe 35,4 mglkg pro Tag, 11,6 SD; Kontrollgruppe 31,l mg/kg pro Tag, SD 6,6). Der mittlere Plasma VPA-Spiegel war s i g n a a n t niedriger , in der experimentellen Gruppe (63,O pg/ml, SD 21,8) als in der Kontrollgruppe (99,3 pg/ml, SD 23,3), p < 0.01. Das Verhatnis VPA-Spiegel: Dosis (LDR' war in der experimentellen Gmppe ebenfalls reduziert (1,92, SD 0,75) gegeniiber der Kontrollgruppe (3,26, SD 0,65), p < 0.01. Innerhalb der experimentellen Gruppe waren die VPA-Spiegel und die VPNLDR bei Patienten, die entweder Phenytoin oder Phenobarbital bekamen, signifikant erniedrigt. Die mittlere VPADosis war nicht signifikant unterschiedlich in der experimentellen und in der Kontrollgruppe. Diese Daten lassen vermuten, daR andere Antiepileptika signifikanterweise den Steady-state-Spiegel im Hinblick auf die verabfolgte Dosis VPA andern.
(D. Scheffner, Heidelberg)
